Skip to content
Insider tapeLive · 5:07 PM ET
My stocks

Moderna (MRNA) insider trading

Insider activity, historical context and SEC filings · data through Nov 20, 2026

Health CareBiotechnologyMRNA

Closing price · Nov 19, 2026 $200.20 +1.7% on the day · +728.0% over 12 months 52-week range $22.36 – $269.00
Get MRNA alerts
Open-market purchases0 insidersno buys · last 12 months
Insiders selling6last 12 months
Reported sales$98.5M24 of 26 recent sales pre-planned (10b5-1)
In 15 seconds

No open-market insider buying in the last 12 months. Selling alone is common (taxes, diversification, pre-planned 10b5-1 sales) and isn't treated as a signal here.

Label: Heavy selling · based on open-market trades (codes P and S), last 12 months. Not a rating or advice.
  • Next earnings expected around Feb 5, 2027 (estimate from past release dates). Insiders usually trade in the weeks after results; past reactions ↓
Latest open-market trade

Sale Stephen Hoge, President sold 39,160 shares at $219.66 ($8.6M).

Trade date
Nov 16, 2026
Disclosed to the SEC
Nov 18, 2026
Type
Pre-planned sale, 10b5-1 (code S)

Read the original SEC filing ↗All MRNA insider trades ↓

Insiders have two business days to report a trade to the SEC, so filings (and our alerts) always come after the trade, never in real time.

MRNA insider transactions (Form 4)

Open-market purchases and sales. 139 grants, option exercises and tax withholdings are not shown.

Filed Insider Type Shares Price Value Since Score
Nov 18SEC Stephen HogePresident Sell Plan 39,1601,673,858 held (−2%) $219.66 $8.6M -8.9% —
Nov 18SEC Stephen HogePresident Sell Plan 33,9761,316,334 held (−3%) $211.45 $7.2M -5.3% —
Nov 18SEC Stephen HogePresident Sell Plan 5,0821,311,252 held (−0%) $212.57 $1.1M -5.8% —
Nov 18SEC Stephen HogePresident Sell Plan 1571,311,095 held (−0%) $214.19 $34K -6.5% —
Oct 16SEC Stephen HogePresident Sell Plan 39,1451,636,565 held (−2%) $220.72 $8.6M -9.3% —
Oct 16SEC Stephen HogePresident Sell Plan 38,7741,599,708 held (−2%) $213.47 $8.3M -6.2% —
Oct 16SEC Stephen HogePresident Sell Plan 4501,599,258 held (−0%) $214.15 $96K -6.5% —
Sep 16SEC Stephen HogePresident Sell Plan 40,2811,562,029 held (−3%) $146.07 $5.9M +37.1% —
Sep 16SEC Stephen HogePresident Sell Plan 40,2941,525,858 held (−3%) $144.13 $5.8M +38.9% —
Sep 14SEC James M. MockCFO Sell Plan 19,83674,375 held (−21%) $134.49 $2.7M +48.9% —
Sep 14SEC James M. MockCFO Sell Plan 15,00059,375 held (−20%) $134.49 $2.0M +48.9% —
Sep 3SEC Shannon Thyme KlingerGeneral Counsel Sell Plan 3,47174,129 held (−4%) $139.95 $486K +43.1% —
Aug 7SEC Stephane BancelCEO Sell Plan 187,0446,187,791 held (−3%) $58.79 $11.0M +240.5% —
Aug 7SEC Stephane BancelCEO Sell Plan 147,4736,539,564 held (−2%) $56.21 $8.3M +256.2% —
Aug 7SEC Stephane BancelCEO Sell Plan 124,8386,414,726 held (−2%) $56.96 $7.1M +251.5% —
Aug 7SEC Stephane BancelCEO Sell Plan 39,8916,374,835 held (−1%) $58.12 $2.3M +244.5% —
Jul 16SEC Stephen HogePresident Sell Plan 53,3361,483,848 held (−3%) $67.60 $3.6M +196.2% —
Jun 17SEC Stephen HogePresident Sell Plan 53,3361,483,848 held (−3%) $51.37 $2.7M +289.7% —
Jun 8SEC Shannon Thyme KlingerGeneral Counsel Sell Plan 3,47167,468 held (−5%) $50.00 $174K +300.4% —
May 22SEC Noubar AfeyanDirector Sell 9,2633,924 held (−70%) $46.84 $434K +327.4% —
May 18SEC Stephen HogePresident Sell Plan 53,3361,477,997 held (−3%) $48.40 $2.6M +313.6% —
May 4SEC Abbas HussainDirector Sell Plan 5,68212,066 held (−32%) $46.63 $265K +329.3% —
Mar 3SEC Shannon Thyme KlingerGeneral Counsel Sell Plan 13,88559,689 held (−19%) $52.29 $726K +282.9% —
Feb 25SEC Stephen HogePresident Sell Plan 160,0091,457,427 held (−10%) $48.84 $7.8M +309.9% —
Dec 15SEC Noubar AfeyanDirector Sell 23,8533,924 held (−86%) $29.48 $703K +579.0% —
Dec 11SEC Abbas HussainDirector Sell Plan 5041,515 held (−25%) $27.60 $14K +625.4% —
Historical context

Similar past setups: not applicable. MRNA has had no open-market insider purchases in the last 12 months, so there's no buying setup to compare with history. When insiders buy, this section shows how 6,290 similar past buys did over 90 days. How we calculate this →

Play with MRNA in the Research Lab

MRNA has no open-market insider buys in the last 12 months. Try the tools with any setup.

All tools →

Quick backtest: did buys like this beat the market?

Insiders buying
CEO or CFO
Dollar size
Stock before

Tap a setting to see how 6,290 past insider buys did.

Open the full Backtester →

Share price and insider trades

MRNA closeInsider buyInsider sale
0100200300DecJan 2026FebMarAprMayJunJulAugSepOctNovEEarnings release filed 2026-01-12EEarnings release filed 2026-02-13EEarnings release filed 2026-05-01EEarnings release filed 2026-07-31EEarnings release filed 2026-11-06Sold $13,910 on 2025-12-09 · Abbas HussainSold $173,550 on 2026-06-04 · Shannon Thyme KlingerSold $264,952 on 2026-05-01 · Abbas HussainSold $433,879 on 2026-05-21 · Noubar AfeyanSold $485,766 on 2026-09-01 · Shannon Thyme KlingerSold $703,306 on 2025-12-11 · Noubar AfeyanSold $726,047 on 2026-03-02 · Shannon Thyme KlingerSold $2,581,462 on 2026-05-15 · Stephen HogeSold $2,739,870 on 2026-06-15 · Stephen HogeSold $3,605,514 on 2026-07-15 · Stephen HogeSold $4,685,094 on 2026-09-10 · James M. MockSold $5,807,574 on 2026-09-14 · Stephen HogeSold $5,883,846 on 2026-09-15 · Stephen HogeSold $7,814,840 on 2026-02-23 · Stephen HogeSold $8,298,134 on 2026-11-17 · Stephen HogeSold $8,373,453 on 2026-10-14 · Stephen HogeSold $8,601,886 on 2026-11-16 · Stephen HogeSold $8,640,084 on 2026-10-15 · Stephen HogeSold $28,715,011 on 2026-08-05 · Stephane Bancel
Bought, 12 months$0
Sold, 12 months$98.5M
Insiders buying0
Insiders selling6

Moderna insider trading at a glance (Nov 20, 2026): in the past 12 months, 0 insiders bought $0 and 6 sold $98.5M of MRNA stock on the open market.

By InsiderPrint Research Desk · Updated · Sources: SEC EDGAR Form 4 filings, FINRA short-sale volume · How we calculate this

MRNA insider buying and selling by quarter

Open-market purchases (green, above the line) and sales (red, below), by trade date.

Q4 2025: $717K sold (2 trades)Q4 2025Q1 2026: $8.5M sold (2 trades)Q1 2026Q2 2026: $6.2M sold (5 trades)Q2 2026Q3 2026: $49.2M sold (10 trades)Q3 2026Q4 2026: $33.9M sold (7 trades)Q4 2026
QuarterBoughtPurchasesSoldSales
Q4 2026—0$33.9M7
Q3 2026—0$49.2M10
Q2 2026—0$6.2M5
Q1 2026—0$8.5M2
Q4 2025—0$717K2

Valuation, profit and volume

P/E (trailing)Not meaningful (no profit)Sector median 25.0
Market value$87.30BBiotechnology
Profit margin-141.4%Revenue growth +2.1%
Volume vs. 50-day0.5×Last 5 sessions

Source: Yahoo Finance, as of Nov 2, 2026. Volume and paper profit use daily closing prices.

Summary

Over the past 12 months, 0 Moderna insiders reported open-market purchases totaling $0, while 6 insiders reported sales totaling $98.5M. 24 of 26 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.

MRNA earnings: how the stock reacted

Each quarterly results release (SEC 8-K Item 2.02), the trend before it, insider trades in the 30 days before, and the 2-day market reaction. “E” marks releases on the chart above.

Does it matter? →
Release15 days beforeInsiders, 30 days beforeReaction (2 days)Next 30 days
Nov 6, 2026 -1.8% Sold $17.0M +11.4%S&P +2.7% pending
Jul 31, 2026 -15.2% Sold $3.6M -4.8%S&P +2.2% +173.5%
May 1, 2026 -15.3% None +3.0%S&P -0.1% +3.7%
Feb 13, 2026 -11.5% None +9.5%S&P +0.2% +19.2%
Jan 12, 2026 +4.7% None +15.5%S&P -0.0% +1.3%
Nov 6, 2025 -14.3% None +4.2%S&P -1.0% +12.9%
Aug 1, 2025 -7.8% None -6.5%S&P -0.1% -13.0%
May 1, 2025 +8.8% None -3.3%S&P +2.2% -3.8%

Most companies bar insiders from trading in the weeks before results, so pre-earnings purchases are rare and often made by directors or under pre-set plans. Past reactions don't predict future ones.

MRNA short selling

Daily short-sale volume as a share of trading volume (FINRA), with the 20-day average.

20%40%60%2026-08-26: 61% of volume sold short2026-08-27: 64% of volume sold short2026-08-28: 74% of volume sold short2026-08-31: 62% of volume sold short2026-09-01: 60% of volume sold short2026-09-02: 63% of volume sold short2026-09-03: 53% of volume sold short2026-09-04: 54% of volume sold short2026-09-08: 54% of volume sold short2026-09-09: 55% of volume sold short2026-09-10: 53% of volume sold short2026-09-11: 61% of volume sold short2026-09-14: 59% of volume sold short2026-09-15: 65% of volume sold short2026-09-16: 64% of volume sold short2026-09-17: 62% of volume sold short2026-09-18: 63% of volume sold short2026-09-21: 57% of volume sold short2026-09-22: 63% of volume sold short2026-09-23: 61% of volume sold short2026-09-24: 65% of volume sold short2026-09-25: 61% of volume sold short2026-09-28: 62% of volume sold short2026-09-29: 63% of volume sold short2026-09-30: 58% of volume sold short2026-10-01: 61% of volume sold short2026-10-02: 64% of volume sold short2026-10-05: 58% of volume sold short2026-10-06: 66% of volume sold short2026-10-07: 64% of volume sold short2026-10-08: 69% of volume sold short2026-10-09: 62% of volume sold short2026-10-12: 61% of volume sold short2026-10-13: 65% of volume sold short2026-10-14: 65% of volume sold short2026-10-15: 67% of volume sold short2026-10-16: 66% of volume sold short2026-10-19: 71% of volume sold short2026-10-20: 68% of volume sold short2026-10-21: 70% of volume sold short2026-10-22: 65% of volume sold short2026-10-23: 60% of volume sold short2026-10-26: 65% of volume sold short2026-10-27: 57% of volume sold short2026-10-28: 55% of volume sold short2026-10-29: 52% of volume sold short2026-10-30: 56% of volume sold short2026-11-02: 56% of volume sold short2026-11-03: 63% of volume sold short2026-11-04: 60% of volume sold short2026-11-05: 51% of volume sold short2026-11-06: 60% of volume sold short2026-11-09: 59% of volume sold short2026-11-10: 52% of volume sold short2026-11-11: 54% of volume sold short2026-11-12: 59% of volume sold short2026-11-13: 42% of volume sold short2026-11-16: 47% of volume sold short2026-11-17: 50% of volume sold short2026-11-18: 48% of volume sold shortAug 26Sep 10Sep 24Oct 8Oct 22Nov 5
Latest (Nov 18): 48%20-day average: 58%Prior 2 months: 63%

This is short volume from off-exchange trades, not short interest. It includes market makers' routine hedging, so 40–50% is normal; what stands out is a ratio well above the stock's own average. Insiders buying while shorts pile in →

Insiders at Moderna

InsiderBoughtSoldLast filingPast buys beat S&PScore
Stephen HogePresident — $62.3M Nov 18, 2026 — —
Stephane BancelCEO — $28.7M Aug 7, 2026 0 of 1 —
James M. MockCFO — $4.7M Oct 7, 2026 — —
Shannon Thyme KlingerGeneral Counsel — $1.4M Sep 8, 2026 — —
Noubar AfeyanDirector — $1.1M May 22, 2026 — —
Abbas HussainDirector — $279K May 4, 2026 — —
Elizabeth E. TallettDirector — — May 4, 2026 — —
Francois NaderDirector — — May 4, 2026 — —
Elizabeth G. NabelDirector — — May 4, 2026 — —
David M. RubensteinDirector — — May 4, 2026 — —
Sandra HorningDirector — — May 4, 2026 — —

Board links: companies that share insiders with MRNA

Directors and executives who filed Form 4s for MRNA and another company in the last 12 months.

See the map →
  • CGCarlyle Group David M. Rubenstein Director here · Director at CG · latest filing Sep 11, 2026
  • GILDGilead Sciences Sandra Horning Director here · Director at GILD · latest filing May 4, 2026
  • MDTMedtronic Elizabeth G. Nabel Director here · Director at MDT · latest filing May 4, 2026

Insider activity at other Health Care companies

Same sector, ranked by insider buying in the last 90 days.

  • KODKodiak Sciences Inc.$181M bought
  • BBTXBambusa Therapeutics, Inc.$52.6M bought
  • WWBWINDWARD BIO GROUP AG$49.8M bought
  • ADRXADARx Pharmaceuticals, Inc.$43.4M bought
  • PEPGPepGen Inc.$43.1M bought
  • LYCALycia Therapeutics, Inc.$38.5M bought

MRNA stock: common questions

Are Moderna insiders buying MRNA stock?

No. No Moderna insider reported an open-market purchase of MRNA in the past 12 months.

Are Moderna insiders selling MRNA stock?

6 insiders reported sales worth $98.5M over the same period.

Where does this data come from?

Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.

What is MRNA's 52-week range?

Over the past year MRNA has traded between $22.36 and $269.00. It last closed at $200.20 on Nov 19, 2026.